2-(Oxolan-3-yl)acetic acid → N-[4-(morpholin-4-yl)-1-oxophthalazin-2(1H)-yl]-2-(tetrahydrofuran-3-yl)acetamide

HRID 535513

反応式

HRID 535513 の反応式
[NH2:1][N:2]1[N:11]=[C:10]([N:12]2[CH2:17][CH2:16][O:15][CH2:14][CH2:13]2)[C:9]2[C:4](=[CH:5][CH:6]=[CH:7][CH:8]=2)[C:3]1=[O:18].[O:19]1[CH2:23][CH2:22][CH:21]([CH2:24][C:25](O)=[O:26])[CH2:20]1>>[N:12]1([C:10]2[C:9]3[C:4](=[CH:5][CH:6]=[CH:7][CH:8]=3)[C:3](=[O:18])[N:2]([NH:1][C:25](=[O:26])[CH2:24][CH:21]3[CH2:22][CH2:23][O:19][CH2:20]3)[N:11]=2)[CH2:17][CH2:16][O:15][CH2:14][CH2:13]1

参加物

3

反応物 2

HCID 42449052-(Oxolan-3-yl)acetic acidHCID 709761042-amino-4-morpholinophthalazin-1(2H)-one

生成物 1

HCID 70975906N-[4-(morpholin-4-yl)-1-oxophthalazin-2(1H)-yl]-2-(tetrahydrofuran-3-yl)acetamide

実験手順

The product from Example 1B and 2-(tetrahydrofuran-3-yl)acetic acid were processed using a method similar to that described in Example 10C to afford the title compound. 1H NMR (500 MHz, CDCl3) δ ppm 8.44-8.46 (m, 1H), 8.27-8.29 (bs, 1H), 7.89-7.94 (m, 1H), 7.80-7.86 (m, 1H), 7.74-7.79 (m, 1H), 3.91-3.98 (m, 6H), 3.70-3.82 (m, 1H), 3.57-3.61 (m, 1H), 3.21-3.23 (m, 4H), 2.77-2.81 (m, 1H), 2.51-2.54 (m, 2H), 2.15-2.30 (m, 1H), 1.68-1.78 (m, 1H); MS (APCI+) M/Z 359 (M+H)+.

出典と根拠

ORDレコード
ord-a61851261451479eac7b85b0c7f4ec09
出典データセット
uspto-grants-2014_10
特許番号
US08859549B2

関連ノート

読み込み中…